A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

56 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase I study will be performed in a double-blind, randomized, crossover design in healthy male and female subjects. The central ECG laboratory will be blinded to treatment. Every effort will be made to enroll equal numbers of males and females into the study.

Eligible subjects will participate in a screening phase (within 28 days of the dosing day), a treatment phase and a final visit, which will be conducted on discharge from the study. Study duration will be 32 days with a total of approximately 12 days of confinement. During the resting ECG periods, 12-lead digital ECGs will be extracted from continuous telemetry at selected time points to assess potential ECG effects. Blood samples for PK evaluation will be collected in conjunction with the ECG time points.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652

Hypertension Mineralocorticoid Receptor Antagonist

COMPLETED PHASE1

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

NCT05355935

Healthy Volunteer

COMPLETED PHASE1

Thorough QT Assessment of Cedazuridine in Healthy Subjects

NCT04953923

Healthy Volunteers

COMPLETED PHASE1

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

NCT00532610

Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

NCT01199523

Healthy Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

APF530 Exposure, Granisetron and Moxifloxacin, Placebo

Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo

Withdraw treatment

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Withdraw treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects in good health
* aged between 18-50 years
* weigh at least 50 kg (110 pounds)
* have a body mass index of 18-32 kg/m2 inclusive
* capable of understanding and complying with the protocol
* have signed the informed consent

Exclusion Criteria

* have a history of drug abuse or are current smokers
* have a known hypersensitivity to Moxifloxacin or granisetron
* a history or presence of clinically significant abnormal 12-lead ECG or an ECG with QTc by Bazett's correction of \> 450 ms in men, \> 470 ms in women on the screening ECG
* PR \> 240 ms, QRS \> 110 ms or a history of prolongation of QT interval
* a family history of Long QT Syndrome or cardiac disease
* may not have used any medications or consumed any foods contraindicated in the protocol

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes